Researchers halt small study aimed at Fine-Tuning scleroderma treatment
NCT ID NCT04244916
Summary
This study aimed to find the best blood level of the drug mycophenolate mofetil (MMF) to treat skin thickening and lung problems in people with systemic sclerosis (scleroderma). It was an observational study that planned to follow patients for one year to see if specific drug levels led to better improvements in skin and breathing tests. The study was terminated early after enrolling only two participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin hospital, AP-HP
Paris, France, 75014, France
Conditions
Explore the condition pages connected to this study.